FY2025 Earnings Forecast for Pfizer Issued By Zacks Research

Pfizer Inc. (NYSE:PFE - Free Report) - Equities research analysts at Zacks Research lowered their FY2025 earnings per share estimates for Pfizer in a report released on Monday, October 21st. Zacks Research analyst K. Shah now anticipates that the biopharmaceutical company will post earnings per share of $2.79 for the year, down from their prior estimate of $2.81. The consensus estimate for Pfizer's current full-year earnings is $2.66 per share. Zacks Research also issued estimates for Pfizer's Q1 2026 earnings at $0.71 EPS, Q2 2026 earnings at $0.64 EPS, Q3 2026 earnings at $0.79 EPS and FY2026 earnings at $2.96 EPS.

A number of other analysts have also weighed in on PFE. Daiwa Capital Markets upgraded shares of Pfizer from a "neutral" rating to an "outperform" rating and raised their target price for the company from $28.00 to $34.00 in a research report on Wednesday, August 7th. Daiwa America upgraded Pfizer from a "moderate buy" rating to a "strong-buy" rating in a research report on Wednesday, August 7th. Sanford C. Bernstein initiated coverage on Pfizer in a report on Thursday, October 17th. They issued a "market perform" rating and a $32.00 target price for the company. StockNews.com raised Pfizer from a "hold" rating to a "buy" rating in a research note on Wednesday, October 9th. Finally, Barclays upped their price objective on Pfizer from $30.00 to $32.00 and gave the company an "equal weight" rating in a research note on Wednesday, July 31st. Seven analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $33.91.

Pfizer Price Performance

Shares of PFE traded down $0.09 during mid-day trading on Tuesday, reaching $28.85. The company had a trading volume of 29,015,157 shares, compared to its average volume of 37,000,074. The company's 50 day simple moving average is $29.07 and its 200 day simple moving average is $28.48. The company has a market capitalization of $163.46 billion, a price-to-earnings ratio of -62.71, a P/E/G ratio of 1.02 and a beta of 0.67. Pfizer has a 1-year low of $25.20 and a 1-year high of $31.54. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, topping analysts' consensus estimates of $0.46 by $0.14. The company had revenue of $13.28 billion during the quarter, compared to analysts' expectations of $12.96 billion. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. Pfizer's revenue was up 2.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.67 EPS.

Institutional Trading of Pfizer

A number of institutional investors have recently bought and sold shares of PFE. Olistico Wealth LLC bought a new stake in shares of Pfizer during the 2nd quarter valued at about $25,000. MFA Wealth Advisors LLC bought a new position in shares of Pfizer during the 2nd quarter worth approximately $29,000. Quarry LP acquired a new stake in shares of Pfizer during the 2nd quarter worth approximately $31,000. Trivant Custom Portfolio Group LLC increased its stake in shares of Pfizer by 100.0% in the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company's stock valued at $33,000 after acquiring an additional 600 shares in the last quarter. Finally, Financial Connections Group Inc. acquired a new position in shares of Pfizer during the second quarter valued at about $34,000. Institutional investors own 68.36% of the company's stock.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be paid a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.82%. The ex-dividend date of this dividend is Friday, November 8th. Pfizer's dividend payout ratio is currently -365.21%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.